

July 8, 2016

Announcements

Integrative Medicine Program Launches at Smilow

We are proud to announce that Smilow Cancer Hospital now has Integrative Medicine clinical consultations available to our patients. Led by Ather Ali, ND, MPH, MHS, the program provides patients at Smilow Cancer Hospital and our Care Centers with access to dedicated resources to give guidance on the risks and benefits of using dietary supplements/natural products, acupuncture, massage, meditation, and other complementary therapies. The Smilow Integrative Medicine Program provides an evidence-based and conservative approach, working in conjunction with mainstream care, to promote safe and effective patient care.

Dr. Ali has extensive experience in the integrative management of chronic disease for patients, as well as teaching patients to optimize their health from a holistic perspective. He is trained in naturopathic medicine, integrative medicine, epidemiology, and patient-oriented research. To refer a patient for a consultation, please call (203) 200-HEAL or select YNH SMILOW INTEGRATIVE MEDICINE [101010097] through the EPIC referral system.

Annual ASCO Review a Success

from the desk of

Peter G. Schulam, MD, PhD

Director, Yale Cancer Center
and Physician-in-Chief,
Smilow Cancer Hospital (Interim)

Yale
NewHaven
Health

Smilow Cancer
Hospital

Yale **CANCER
CENTER**

A Comprehensive Cancer Center Designated
by the National Cancer Institute

Recent News

Read recent articles featuring experts from
Yale Cancer Center

[News Center >>](#)

LATEST ARTICLES:



Yale Cancer Center and Smilow Cancer Hospital welcomed over 150 community physicians to New Haven on Friday, June 24 for our 8th annual ASCO Review, hosted by Dr. Roy Herbst and Dr. Howard Hochster, to provide updates on treatment options and clinics trials for patients. The full day symposium included presentations and case presentations by 22 of our faculty members from both the main campus and our Care Centers highlighting the latest advances in clinical care and clinical trial opportunities. Melinda Irwin, MPH, PhD, Associate Director for Population Sciences, gave the keynote address on *Energy Balance: The New Adjuvant Therapy*. Thank you to all those who participated and spent time preparing and presenting.

Drs. Arthur Levy and Leonard Farber Retire



Vince DeVita, Art Levy, Len Farber, and Roy Herbst



New Technique May Help Predict Outcomes for Patients With Glioblastoma Multiforme

[Read More >>](#)



CMS Oncology Care Model selects Smilow Cancer Hospital

[Read More >>](#)



After over 40 years at YNHH, Dr. Arthur Levy and Dr. Leonard Farber have retired from clinical practice. Drs. Farber and Levy began practicing oncology together in 1970s when they launched Medical Oncology & Hematology, building a group that ultimately became our first Care Centers in 2012. Dr. Roy Herbst, Chief of Medical Oncology commented, "Art and Len are outstanding colleagues and superb role models for our faculty and fellows. They have always focused on the needs of their patients. Their knowledge and continued dedication to Smilow Cancer Hospital and our Care Centers was an example for us all and I hope they will remain involved in the teaching and education of our students and fellows. Their compassionate care truly exemplifies the art of medicine."

Notables

Steven Bernstein, MD, a member of our Cancer Prevention and Control Research Program, has received a 4-year, \$2.7 million R01 entitled 'Optimizing Tobacco Dependence Treatment in the Emergency Department.' The goal of the project is to determine which combination of treatment strategies is most effective, and cost-effective, in promoting smoking cessation in smokers visiting the Yale ED. He and his team are testing the efficacy of nicotine patch and gum, motivational interviewing, Quitline referral, and smartphone texting in a novel 16-arm factorial trial using the Multiple Optimization Strategy (MOST) study design. This study builds off a previous NCI-supported project at Yale, which led to the first successful trial of ED-initiated smoking cessation treatment.

At the 2016 Commencement, Yale School of Medicine awarded **The Francis Gilman Blake Award** for outstanding teaching of the medical sciences to **Anthony Kim, MD**, Associate Professor of Surgery (Thoracic Surgery) and a member of our Cancer Prevention and Control Research Program.

Employee Profile: Karen Hammond

Yale Cancer Center doctor seeing 'some dramatic responses' with bladder cancer drug

[Read More >>](#)



The National Cancer Moonshot Summit: what are the key priorities?

[Read More >>](#)



Dr. Chagpar on Surgical Treatment of Patients With HER2+ Breast Cancer

[Read More >>](#)

Karen Hammond, MSN, APRN, ACNP-BC, AOCNP, Oncology Nurse Practitioner at the Smilow Cancer Hospital Care Center at Waterbury, began her career in 1981 as an oncology staff nurse. In 2000, she earned her Masters degree in Nursing from Yale School of Nursing with board certification in acute care and oncology.




Karen is a Clinical Instructor for Yale School of Nursing and is committed to teaching as well as mentoring future generations. "I feel it is very important to give back and prepare the next generation to provide high quality, evidence-based care. I love working with recent graduates, before they set-up their own practice, to share my knowledge and help them be successful."

In addition to her administrative tasks, Karen takes great pride in caring for her many patients. "I am humbled every day by the physical and emotional challenges that my patients and their families struggle with," said Karen. "I am privileged to be able to help them through the entire trajectory of care and hopefully through survivorship. All of this would not be possible without my caring and dedicated team to make my job that much easier."

Lisa Shomsky, MBA, RN, CNML, Clinical Program Manager for the Smilow Care Centers, commented, "Karen is an integral part of the Smilow Waterbury team. She is always accessible to the nursing staff who trust that her judgment and her patient assessments are thorough and accurate. Karen loves to teach and share knowledge with patients, families, and staff. She gives monthly in-services to nursing staff, many of which improve triage knowledge and response to patient calls."

Funding & Award Opportunities



Study: Receptor suppresses the immune response in order to save it

[Read More >>](#)

Join Yale Cancer Center on Facebook

Like us on Facebook 

LATEST POSTS:

Thank you Sikorsky Teamsters Local 1150 for your donation to Smilow Cancer Hospital from your annual "Teamsters for Tomorrow" family picnic! We appreciate your support!



[Read More >>](#)

As he prepared to wrap up his medical residency in neurosurgery, Dr. Paul Kalanithi, a graduate of Yale Medical School, was diagnosed with terminal lung cancer. In the last years of his life, before passing away at the age of 37, Paul continued to care for patients. He and his wife, Dr. Lucy Kalanithi, became parents. And Paul wrote the critically acclaimed book, *When Breath*

All current funding opportunities are archived on the Yale Cancer Center website, and searchable by topic, funding agency, and due date. Please check the site often for new opportunities.

[Learn More >>](#)

Yale SPORE in Skin Cancer Developmental Research Awards

Developmental Research Program Awards are intended to support a broad spectrum of innovative pilot projects applicable to human skin cancer risk, prevention, diagnosis, prognosis, or treatment. To be funded, DRP projects must have promising translational research potential with application to human skin cancer, and there must be the expectation that they can evolve into, full projects with a clear translational component funded either within this SPORE or as independent R01 (or equivalent) grants.

Application Deadline: July 11, 2016

[Learn More >>](#)

Susan G. Komen 2016/2017 Letter of Intent Announcements

1. CAREER CATALYST RESEARCH GRANTS (CCR)

CCR Grants provide unique opportunities for scientists who have held faculty positions for no more than five years at the time of Application to achieve research independence. CCR grants provide support for hypothesis-driven research projects that have significant potential to advance our understanding of breast cancer, lead to reductions in breast cancer incidence and/or mortality, and move us toward the goal of a world without breast cancer. There are two research focus areas: Basic/Translational and Clinical.

Letter of Intent due by 1pm, EST (U.S.) on Thursday, July 14, 2016

[Learn More >>](#)

2. POSTDOCTORAL FELLOWSHIP GRANTS

PDF Grants are intended to attract and preserve today's young scientists and clinicians who will fuel the future and become the next generation of leaders in the field of breast cancer research. These leaders will play key roles in reducing breast cancer incidence and

Becomes Air, a reflection on being a doctor with a terminal illness.

Watch Lucy, also a graduate of Yale Medical School, talk with the Huffington Post about how suffering became an invitation to love and to be loved.



[Read More >>](#)

When standard treatments failed to reverse Renee Shine's lung cancer, the 64-year-old realtor turned to Yale Cancer Center's Dr. Patricia M. LoRusso for help. Renee enrolled in a clinical trial for Keytruda, a promising immunotherapy. "If she didn't go on this clinical trial, she had no more than a year-at most-to live," LoRusso said. But Renee has thrived in the face of cancer because of this clinical trial.



Renee has **thrived** in the face of cancer

[Read More >>](#)

When Bob Carlson was diagnosed with stage IV non-small cell lung cancer, he had no symptoms. His cancer was found by chance during a CT scan. After several rounds of chemotherapy, Bob met with Yale Cancer Center's Dr. Roy Herbst to discuss the possibility of joining a clinical trial. Shortly thereafter, Bob joined a trial using the immunotherapy atezolizumab, which has shrunk his tumors and kept his cancer at bay. Thanks to patients like Bob,

mortality within the next decade, with the ultimate goal of ending breast cancer forever. There are 2 Research Focus Areas: Basic/Translational and Clinical.

Letter of Intent due by 1pm, EST (U.S.) on Thursday, July 14, 2016

[Learn More >>](#)

3. GRADUATE TRAINING IN DISPARITIES RESEARCH (GTDR) GRANTS

GTDR Grants are intended to establish and/or to sustain a training program for graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups.

Application Due: September 2016

[Learn More >>](#)

Cooperative Agreement to Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (U01)

The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement (U01) applications that propose studies to enhance pre-clinical in vitro and in vivo testing of NCI-prioritized molecularly targeted anti-cancer agents for use with radiation therapy combined with systemic chemotherapy.

Application Due: July 14, 2016

[Learn More >>](#)

Lung Cancer Research Program Funding Opportunities for Fiscal Year 2016 (FY16)

The FY16 Defense Appropriations Act provides \$12 million (M) to the Department of Defense (DoD) Lung Cancer Research Program (LCRP) to support innovative, high-impact lung cancer research. The LCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.

Concept Award

Investigators at all academic levels. Supports highly innovative, untested, potentially groundbreaking concepts in lung cancer.

Preproposal Due: July 28, 2016

[Learn More >>](#)

atezolizumab is now fast-tracked for FDA approval.





[Read More >>](#)

Follow Yale Cancer Center on Twitter


Follow us on [twitter](#)


LATEST TWEETS:


 #TBT the birth of #chemotherapy @YNHH back in 1942.

 New Technique May Help Predict Outcomes for Patients With #Glioblastom via @CancerTherAdvsr @YaleWestCampus #btsm

 Stop by @YNHH until 2pm today to learn about #UVSafetyMonth and #skinsafety. #WellnessWednesday

 Join us Wednesday, July 6 as we celebrate #UVSafetyMonth @YNHH from 11-2. #SunSafety #skincancer #protectyourself

 A new opportunity for #tobacco treatment for smokers with a nodule at risk for lung cancer. bit.ly/29hnZZP #lcsms #tobaccofree #Quit

 @HH_Oncodr chairs session on Immune Therapy in GI Cancer @myESMO today. #immunotherapy #WorldGI

Ovarian Cancer Research Program Funding Opportunities for Fiscal Year 2016

The FY16 Defense Appropriations Act provides \$20 million (M) to the Department of Defense Ovarian Cancer Research Program (OCRP) to support high-impact ovarian cancer research.

Clinical Development Award

Must be an independent investigator at or above the level of Assistant Professor (or equivalent). Supports the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life.

Application Due: August 10, 2016

[Learn More >>](#)

Investigator-Initiated Research Award

Must be an independent investigator at or above the level of Assistant Professor (or equivalent). Supports meritorious basic and clinically oriented research in ovarian cancer.

Application Due: August 10, 2016

Ovarian Cancer Academy Award

Early-Career Investigator. Early-Career Investigator must be within the first 3 years of his/her first faculty position (or equivalent) at the time of submission. Supports the addition of new Early-Career Investigators to the unique, interactive virtual academy that will provide intensive mentoring, national networking, and a peer group for junior faculty.

Application Due: August 10, 2016

Pilot Award


Investigators at or above the postdoctoral level (or equivalent). Supports innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward.


Application Due: August 10, 2016


[Learn More >>](#)


Peer Reviewed Cancer Research Program Funding Opportunities for Fiscal Year 2016

The FY16 Defense Appropriations Act provides \$50 million (M) to the Department of Defense Peer Reviewed Cancer Research Program (PRCRP) to support innovative, high-impact cancer research. The

 @AneesChagpar discusses neoadjuvant trials and surgical options for women with HER+ #breastcancer @Onclive bit.ly/294gEa6 #bcsm

 We're proud to announce our participation in Oncology Care Model @CMSinnovates @YNHH bit.ly/29f10Ik #ValueBasedCare #accountability

 Dr. Silber presented to @ProjectAccessNH on #clinicaltrials & OWN-IT, a project to bring trials to our communities.

 #hcchat #CancerMoonshot A3:20/20 The 25% decrease in #mortality from #cancer we have today has resulted in 1000x return on money invested.

Closer to Free

closer to free

The fund to advance cancer research and enhance patient care

July 11; 10AM

Yale Tobacco Center of Regulatory Science

Connecticut Mental Health Center Auditorium *Public Health Impact and Tobacco Regulatory Science:*

Menthol and More

Jonathan M. Samet, MD, MS

[Read More >>](#)

July 11; 3PM

YCC Special Seminar

Fitkin Amphitheatre, LMP 1094

Hitting Cancer Below the Belt: Targeted Therapy for Ovarian and Prostate Cancer

Alan D. D'Andrea, MD

[Read More >>](#)

July 12; 5:30PM

PRCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY16 PRCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in April and July 2016. Pre-application and application deadlines will be available when the Program Announcements are released.

Horizon Award

PI: A predoctoral candidate within two years of successfully passing qualifying examinations or a postdoctoral fellow within three years of completion of his/her terminal degree (excluding medical residency or family medical leave).

Application Due: August 17, 2016

[Learn More >>](#)

Department of Defense Prostate Cancer Research Program Funding Opportunities for Fiscal Year 2016

The FY16 Defense Appropriations Act provides \$80 million (M) to the Department of Defense Prostate Cancer Research Program (PCRP) to support innovative, high-impact prostate cancer research.

Clinical Consortium Research Site Award

Independent investigators at or above the level of Assistant Professor (or equivalent). Supports the addition of a Clinical Research Site to the Prostate Cancer Clinical Trials Consortium. Trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer are encouraged.

Pre-Application Due: September 15, 2016

[Learn More >>](#)

Recent Publications

Transcriptome analysis of human cumulus cells reveals hypoxia as the main determinant of follicular senescence.

Molinari E, Haim B, Pyle AM, **Patrizio P.**

YSM Clinical Research Quarterly Faculty Dinner Series

Cohen Auditorium, NIH E02

Biorepositories

Kevan Herold, MD and David Rimm, MD, PhD

[Read More >>](#)

Submissions

Please submit your recent publication and grant announcements to:

Renee Gaudette

Director, Public Affairs and Marketing

renee.gaudette@yale.edu

 [Forward to a Friend](#)

Mol Hum Reprod. 2016 Jun 6.

[Read More >>](#)

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW, Juergens RA, Laurie SA, Nathan FE, Shen Y, Harbison CT, Hellmann MD.

J Clin Oncol. 2016 Jun 27.

[Read More >>](#)

Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells.

Forloni M, Gupta R, Nagarajan A, Sun LS, Dong Y, Pirazzoli V, Toki M, Wurtz A, Melnick MA, Kobayashi S, Homer RJ, Rimm DL, Gettinger SJ, Politi K, Dogra SK, Wajapeyee N.

Cell Rep. 2016 Jun 21.

[Read More >>](#)

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM.

Lancet Oncol. 2016 Jun 3.

[Read More >>](#)

Probe for the measurement of cell surface pH in vivo and ex vivo.

Anderson M, Moshnikova A, Engelman DM, Reshetnyak YK, Andreev OA.

Proc Natl Acad Sci U S A. 2016 Jul 5.

[Read More >>](#)

Improved Visibility of Metastatic Disease in the Liver During Intra-Arterial Therapy Using Delayed Arterial Phase Cone-Beam CT.

Scherthaner RE, Haroun RR, Duran R, Lee H, Sahu S, Sohn JH, Chapiro J, Zhao Y, Gorodetski B, Fleckenstein F, Smolka S, Radaelli A, van der Bom IM, Lin M, Geschwind JF.

Cardiovasc Intervent Radiol. 2016 Jul 5.

[Read More >>](#)

Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy.

Bossuyt V, Symmans WF.

Ann Surg Oncol. 2016 Jul 5.

[Read More >>](#)

Letter to the editor for "Update of the human and mouse Fanconi anemia genes".

Nebert DW, Dong H, Bruford EA, Thompson DC, Joenje H, Vasiliou V.

Hum Genomics. 2016 Jul 4;10(1):25.

[Read More >>](#)

DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.

Rabenau K, Hofstatter E.

Clin Ther. 2016 Jun 28.

[Read More >>](#)

The Src kinases Hck, Fgr, and Lyn activate Abl2/Arg to facilitate IgG-mediated phagocytosis and Leishmania infection.

Wetzel DM, Rhodes EL, Li S, McMahon-Pratt D, Koleske AJ.

J Cell Sci. 2016 Jun 29.

[Read More >>](#)

Correction of coagulopathy associated with non-bacterial thrombotic endocarditis (NBTE) by surgical debulking in a case of ovarian clear cell carcinoma.

Albright BB, Black JD, Vilaro N, Schwartz PE.

[Read More >>](#)